The Jordan Atrial Fibrillation Study: Baseline Risk Scores and One Year Outcome
NCT ID: NCT03917992
Last Updated: 2023-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2020 participants
OBSERVATIONAL
2019-05-25
2021-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atrial Fibrillation Registry in Jordan
NCT02680483
PREdicting Atrial Fibrillation or Flutter
NCT01851902
Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation
NCT03719144
Studies of Disorders and Mechanisms Related to Atrial Fibrillation Before and After DC-Conversion.
NCT00429884
Demographic Outcomes, and Health Care Resources in Newly Diagnosed Non Valvular AF Patients
NCT04110197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Medical research and clinical studies in Jordan are two basic responsibilities of all medical sectors in the country. Despite the drastic growth and advances of the medical services, the volume of the local medical research is, at best estimate, scarce. The emerging role of private medical groups, in cooperation with other medical sectors and medical schools, in conducting, presenting, and publishing such studies should be encouraged and welcomed by the other medical sectors in the country. A major indicator of judging the credibility and quality of any medical research project is to look at the conferences the research was presented at and the journals it was published in.
This is the 9th major project of the Jordan Collaborating Cardiology Group (JCC) in collaboration with the Jordan AF Study Group. (see Appendix 2. Timeline of our studies) The first project was JoHARTS (1-5) that evaluated coronary risk factors and dyslipidemia in 5000 individuals with ACS, stable CAD, and non CAD patients. The 2nd project was CAPRIS (6,7) evaluated the prognostic implications of hs-CRP in ACS from admission to 1 year. The 3rd project was MINTOR that evaluated onset, triggers, reperfusion strategies and hospital mortality in more than 950 Jordanians with acute ST elevation MI (8-10). The 4th project was GLORY study that evaluated the prevalence of glucometabolic states among ACS patients, prognosis up to 1 year, and TIMI risk score (11-15). The 5th was JoPCR1 that evaluated outcome post PCI in 2426 ACS and non ACS patients in 12 tertiary care centers for the incidence of death, stent thrombosis, revascularization, bleeding, impact of gender, DM, renal dysfunction and age on outcome, GRACE and CRUSADE risk scores (16-18). The 6th is the colchicine study of AF prevention in open heart surgery, one is completed with 1 mg dose and one is ongoing with reduced dose (19). The 7th and 8th projects are ongoing and study statin eligibility in patients admitted with MI (Statin EPIC) and decade or more survivors after coronary revascularization.
The Jordanian AF study, the first of its kind in Jordan, will evaluate patients with AF in an in-patient and out-patient settings.
Study Objectives
1. To study the demographic baseline features of AF patients, risk factors, and comorbid diseases, and types of AF.
2. To study CHADS2 VA2Sc score and HAS BLED scores in these patients.
3. To study patterns of treatment of AF, especially the use of oral anticoagulation and concomitant antiplatelet therapy.
4. To study 1 year incidence of stroke and systemic embolization and other cardiovascular events up to one year of follow up.
5. To present these findings in regional and international conferences and publish them.
The study PI is Dr Nazih Kadri. The assistant to the PI is Dr Eisa Ghanma. The director of the proceedings is Dr A Hammoudeh, and the assistant to the study director, Dr Ahmad Tamari will aid in study clinical initiation, clinical form development, analysis of data and manuscript writing along with the whole team of PI, Co PI, study director and other investigators.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admission with atrial fibrillation or clinic visit for atrial fibrillation
* Signing the consent form
Exclusion Criteria
* Refusal of signing the censent form
* Grave systemic disease with high probability of in hospital death
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ayman J Hammoudeh, MD, FACC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ayman J Hammoudeh, MD, FACC
The Jordanian Comprehensive Center For Electophysiologic Heart Disease
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ayman Hammoudeh, MD, FACC
Role: STUDY_CHAIR
Cardiology Dept, Istishari Hospital, Amman, Jordan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istishari Hospital
Amman, , Jordan
The University of Jordan
Amman, , Jordan
Ep Clinics Khalidi S
Amman, , Jordan
Integrated Center for Cardiovascular and Electric Diseases
Amman, , Jordan
Jordan Hospital
Amman, , Jordan
Khalidi Hospital & Medical Center
Amman, , Jordan
Specialty Hospital
Amman, , Jordan
King Abdullah University Hospital
Irbid, , Jordan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hammoudeh A, Badaineh Y, Tabbalat R, Ahmad A, Bahhour M, Ja'ara D, Shehadeh J, Jum'ah MA, Migdad A, Hani M, Alhaddad IA. The Intersection of Atrial Fibrillation and Coronary Artery Disease in Middle Eastern Patients. Analysis from the Jordan Atrial Fibrillation Study. Glob Heart. 2024 Mar 12;19(1):29. doi: 10.5334/gh.1312. eCollection 2024.
Alrabadi N, Al-Nusair M, Haddad R, Alburie L, Mhaidat N, Aljarrah M, Hamoudeh A. Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study. Eur J Clin Pharmacol. 2024 Apr;80(4):545-552. doi: 10.1007/s00228-024-03622-8. Epub 2024 Jan 23.
Al-Makhamreh H, Alrabadi N, Haikal L, Krishan M, Al-Badaineh N, Odeh O, Barqawi T, Nawaiseh M, Shaban A, Abdin B, Khamies L, Hammoudeh A. Paroxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study. Int J Environ Res Public Health. 2022 May 19;19(10):6173. doi: 10.3390/ijerph19106173.
Alhaddad Z, Hammoudeh A, Khader Y, Alhaddad IA. Demographics and Risk Profile of Elderly Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. Vasc Health Risk Manag. 2022 Apr 15;18:289-295. doi: 10.2147/VHRM.S360822. eCollection 2022.
Hammoudeh AJ, Khader Y, Kadri N, Al-Mousa E, Badaineh Y, Habahbeh L, Tabbalat R, Janabi H, Alhaddad IA. Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. Int J Vasc Med. 2021 Apr 8;2021:5515089. doi: 10.1155/2021/5515089. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JOAF1Y
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.